# CVRx Announces First Patient Enrollment in BENEFIT-HF, a Landmark Heart Failure Trial Evaluating Barostim in Significantly Expanded Population
Canonical URL: https://biopharmsignal.com/news/CVRX/cvrx-announces-first-patient-enrollment-in-benefit-hf-a-landmark-heart-failure-trial-evaluating-barostim-in-significantly-expanded-population
Ticker: CVRX
Company: CVRx
Source: CVRx
Published: 2026-05-04 20:30 EST
Original Source URL: https://ir.cvrx.com
## Summary

MINNEAPOLIS, May 04, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX), a medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced the enrollment of the first patient in the

## Article Body
MINNEAPOLIS, May 04, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX), a medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced the enrollment of the first patient in the
## Recent Company News
- 2026-05-27 20:30 EST — [CVRx to Present at the Goldman Sachs 47th Annual Global Healthcare Conference](https://biopharmsignal.com/news/CVRX/cvrx-to-present-at-the-goldman-sachs-47th-annual-global-healthcare-conference) — Source: CVRx
- 2026-05-20 20:30 EST — [CVRx to Present at the William Blair 46th Annual Growth Stock Conference](https://biopharmsignal.com/news/CVRX/cvrx-to-present-at-the-william-blair-46th-annual-growth-stock-conference) — Source: CVRx
- 2026-05-14 12:00 EST — [CVRx Announces Humana Medicare Advantage Coverage Policy for Barostim Therapy](https://biopharmsignal.com/news/CVRX/cvrx-announces-humana-medicare-advantage-coverage-policy-for-barostim-therapy) — Source: CVRx
- 2026-05-11 20:05 EST — [CVRx Reports First Quarter 2026 Financial and Operating Results](https://biopharmsignal.com/news/CVRX/cvrx-reports-first-quarter-2026-financial-and-operating-results) — Source: CVRx
- 2026-05-04 20:30 EST — [CVRx Announces First Patient Enrollment in BENEFIT-HF, a Landmark Heart Failure Trial Evaluating Barostim in Significantly Expanded Population](https://biopharmsignal.com/news/CVRX/cvrx-announces-first-patient-enrollment-in-benefit-hf-a-landmark-heart-failure-trial-evaluating-barostim-in-significantly-expanded-population) — Source: CVRx
## Related News
- 2026-07-22 20:15 EST — BFRG — [BullFrog AI to Participate in the BTIG Virtual Biotechnology Conference](https://biopharmsignal.com/news/BFRG/bullfrog-ai-to-participate-in-the-btig-virtual-biotechnology-conference-5880a10e)
- 2026-07-22 20:05 EST — AZTA — [Azenta Announces Fiscal 2026 Third Quarter Conference Call and Webcast](https://biopharmsignal.com/news/AZTA/azenta-announces-fiscal-2026-third-quarter-conference-call-and-webcast-48419fff)
- 2026-07-22 20:05 EST — VKTX — [Viking Therapeutics to Report Financial Results for Second Quarter 2026 on July 29, 2026](https://biopharmsignal.com/news/VKTX/viking-therapeutics-to-report-financial-results-for-second-quarter-2026-on-july--bbf2553f)
- 2026-07-22 20:01 EST — AXON — [Axon to Release Second Quarter 2026 Earnings on August 5, 2026](https://biopharmsignal.com/news/AXON/axon-to-release-second-quarter-2026-earnings-on-august-5-2026-66120902)
- 2026-07-22 12:39 EST — ARTL — [New Analysis of Over 50 Studies Showed that All the Non-Prescription CBD Products Researched Fell Short of Therapeutic Efficacy — Reinforcing the Case for Artelo's Optimized ART12.11 CBD Composition](https://biopharmsignal.com/news/ARTL/new-analysis-of-over-50-studies-showed-that-all-the-non-prescription-cbd-product-a3445432)